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Abstract
Colon adenocarcinoma is the third most commonly diagnosed cancer and the second deadliest one. Metabolic
reprogramming, described as an emerging hallmark of malignant cells, includes the predominant use of glycolysis to
produce energy. Recent studies demonstrated that mitochondrial electron transport chain inhibitor reduced colon
cancer tumour growth. Accumulating evidence show that myoferlin, a member of the ferlin family, is highly expressed
in several cancer types, where it acts as a tumour promoter and participates in the metabolic rewiring towards
oxidative metabolism. In this study, we showed that myoferlin expression in colon cancer lesions is associated with
low patient survival and is higher than in non-tumoural adjacent tissue. Human colon cancer cells silenced for
myoferlin exhibit a reduced oxidative phosphorylation activity associated with mitochondrial ﬁssion leading, ROS
accumulation, decreased cell growth, and increased apoptosis. We observed the triggering of a DNA damage
response culminating to a cell cycle arrest in wild-type p53 cells. The use of a p53 null cell line or a compound able to
restore p53 activity (Prima-1) reverted the effects induced by myoferlin silencing, conﬁrming the involvement of p53.
The recent identiﬁcation of a compound interacting with a myoferlin C2 domain and bearing anticancer potency
identiﬁes, together with our demonstration, this protein as a suitable new therapeutic target in colon cancer.
Introduction
Despite an encouraging drop in incidence and mortality,
colon cancer is the third most common diagnosed cancer
independently of gender1. The last GLOBOCAN survey
revealed that 10% of new cancer cases are colon cancer2.
In contrast to what is observed in older people (>50
years), incidence and death rates among younger people
continue to rise1, making this malignancy the second with
the highest mortality rate2, and therefore encouraging us
to sustain our research efforts.
Cancer cells require catabolites to produce energy and
biomass. Metabolic reprogramming of cancer cells
includes the predominant use of glycolysis to produce
energy (Warburg effect)3. However, oxidative phosphor-
ylation (OXPHOS) is also an essential part of their meta-
bolism as it was described to support growth, invasiveness
and confer resistance to chemotherapy in several cancer
types, including colon4–6. Energy metabolism reprogram-
ming, an emerging hallmark of cancer, is necessary for
tumour initiation and progression7. As such, targeting
mitochondrial metabolism appears as a sound potential
approach8. Accordingly, a recent study demonstrated that
a mitochondrial electron transport chain inhibitor
(VLX600) reduced colon cancer tumour growth9.
Energy metabolism is not only driven by intracellular
enzymes but is also conditioned by the intracellular
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availability of nutrients uptaken through speciﬁc trans-
porters. Their abundance at plasma membrane is con-
trolled by several steps, including exocytosis, endocytosis,
and recycling. These processes require myoferlin, a 230-
kDa multiple C2-domain ferlin family member protein,
mainly known for its function in myoblast membrane
fusion10,11. Previously, we have described the high
expression of myoferlin in several cancers12,13 and its
involvement in cancer cell plasma membrane biology
such as endocytosis, membrane receptor recycling, exo-
cytosis, and exosome formation13–15. In a metabolic
context, we have reported myoferlin as a regulator of lipid
metabolism and of mitochondrial dynamics16,17. However,
its mechanism of action remains poorly understood and
unexplored in colon cancer.
In the continuity of our previous studies aiming at
showing the importance of myoferlin in cancer aggres-
siveness and inspired by the lack of information regarding
its expression in colon cancer, we have sought to inves-
tigate this protein in this context. We have found out that
myoferlin expression is highly expressed in colon cancer
and correlates with patient survival. We also have showed
that myoferlin is required to maintain a high OXPHOS
activity and an organised mitochondrial network. We
have discovered, for the ﬁrst time, that myoferlin silencing
produces a DNA damage response and a p53-dependent
cell cycle arrest.
Results
High myoferlin expression in colon cancer lesions is
associated with low survival
Puzzled by the lack of information regarding myoferlin
expression in colon cancer, we decided to mine the
PrognoScan databanks18 to evaluate the consequence of
myoferlin expression on colon cancer patient overall and
disease-speciﬁc survival. We found a highly signiﬁcant
Cox P values (respectively, P < 0.01 and P < 0.001) in the
GSE17536 datasets (n= 177). This result was validated
using the TCGA-COAD data using the OncoLnc tool19.
Kaplan–Meier analysis indicated that myoferlin expres-
sion in the malignant colon lesions was signiﬁcantly
associated with disease-speciﬁc survival. Patients with a
high myoferlin expression have a signiﬁcantly shorter
survival time than in patients with low myoferlin
expression (n= 440, P= 0.01—Fig. 1a). The same asso-
ciation was recently shown in breast16, kidney20, and
pancreas17 cancers. Using TCGA-COAD data, we eval-
uated myoferlin gene expression according to prognostic
stage (Fig. 1b) and Tumour, Node, Metastasis (TNM)
categories (Supplementary ﬁgure S1). Neither the prog-
nostic stage nor any of the TNM categories were asso-
ciated with the myoferlin gene expression. In order to
determine whether myoferlin was an independent prog-
nostic factor, we performed a multivariate Cox survival
analysis with clinical covariates (Supplementary Table 1).
Myoferlin highest percentile was a signiﬁcant (P= 0.039)
factor in the prediction of the disease-speciﬁc survival
with a hazard ratio of 2.618.
We then sought to evaluate myoferlin abundance in a
collection of colon cancer specimens (n= 28). Myoferlin
was strongly stained (mainly scores 2 and 3–76% of the
cases) in the cytoplasm of cancer cells, whereas no or
faintly detectable (mainly scores 0) in adjacent non-
tumoural tissue (Fig. 1c).
Myoferlin is required to maintain a high OXPHOS activity
and an organised mitochondrial network
Recently, we have reported that myoferlin contributes to
OXPHOS in pancreas cancer17. Accordingly, we next
evaluated mitochondrial oxygen consumption rate (OCR)
and mitochondrial network integrity after myoferlin
silencing in colon cancer cell lines expressing highly this
protein: HCT116 and SW480 (Supplementary Fig. 2A).
We inhibited myoferlin translation using small interfering
RNA (siRNA) and monitored the OCR after successive
addition of oligomycin, carbonyl cyanide-p-tri-
ﬂuoromethoxyphenylhydrazone (FCCP), and rotenone/
antimycin A mix. Myoferlin silencing signiﬁcantly
reduced the OCR after FCCP addition in HCT116 and
SW480 cell lines (Fig. 2a). Analysis of respiration com-
partments revealed that maximal OCR was signiﬁcantly
reduced upon myoferlin silencing (Supplementary Figure
S2A and S2G). In the HCT116 cell line, this reduction was
already apparent in basal condition (Supplementary Fig-
ure S2B), while it was not the case in SW480 cell line
(Supplementary Figure S2H). In both cell lines, myoferlin
silencing led to a decrease of the metabolic potential
(Supplementary Figure S2C and S2I). Because of this
signiﬁcant OCR reduction, we decided to evaluate the
mitochondrial morphology (Fig. 2b). In HCT116 and
SW480, the tetramethyl rhodamine ethyl ester (TMRE)-
stained mitochondria appeared as a dense ﬁlamentous
network. When myoferlin was silenced, the mitochondrial
network disappeared and mitochondria turned into indi-
vidual round-shape structures. Indeed, we observed a
signiﬁcant decrease of the number of networked mito-
chondria (Supplementary Figure S2D and S2J), of the
mean mitochondrial network length (Supplementary
Figure S2E and S2K), and of the ratio between the number
of networked and individual mitochondria (Supplemen-
tary Figure S2F and S2L) when myoferlin was silenced.
The mitochondrial network fragmentation induced by
myoferlin silencing was concomitant to a dynamin-related
protein (DRP)-1 phosphorylation on serine 616 (Fig. 2c).
This phosphorylation is known to be implicated in
mitochondrial ﬁssion21. These results suggest that myo-
ferlin is needed to maintain a high and efﬁcient OXPHOS
activity in colon cancer cell lines.
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Myoferlin silencing induces reactive oxygen species (ROS)
accumulation, reduces cell growth, and induces apoptosis
We next explored the consequences of the mitochon-
drial alterations induced by myoferlin silencing in colon
cancer cells. First, as mitochondria are the site of electron
transport chain and as damaged mitochondria are con-
sidered a source of ROS, we measured ROS accumulation.
In comparison to irrelevant siRNA, myoferlin silencing
produced a 40% increase in mitochondrial ROS accu-
mulation (Fig. 3a and Supplementary Figure S3). The
reduced OCR and the accumulation of ROS could inﬂu-
ence cell proliferation. Indeed, myoferlin silencing
decreased sharply (~75%) the HCT116 cell growth and
modestly but signiﬁcantly (~30%) the SW480 one (Fig.
3b). Accordingly, myoferlin-silenced HCT116 cell pro-
duced signiﬁcantly smaller tumours in a chorioallantoic in
ovo model (Supplementary Figure S4). The reduced cell
growth of HCT116 cell line was, at least partially, the
result of an increased (more than two-fold) apoptosis rate
(Fig. 3c). Intriguingly, in SW480 cell line, myoferlin
silencing did not alter the percentage of apoptotic cells,
remaining low (~5%) (Fig. 3c), indicating another
mechanism explaining the low cell growth.
Myoferlin silencing activates p53 and provokes a cell cycle
arrest in HCT116 cell line
Knowing the opposite p53 status of HCT116 (wild
type) and of SW480 (p.R273H; p.P309S), we decided to
investigate the role of p53 in the striking behaviour
difference between the two cell lines upon myoferlin
silencing. We ﬁrst decided to evaluate the p53 abun-
dance and its threonine 81 phosphorylation status in
both cell line after myoferlin silencing (Fig. 4a). Thr81
phosphorylation was evaluated because it is known to be
Fig. 1 High myoferlin expression is associated with lower survival in colon cancer patients. a TCGA-COAD data (http://cancergenome.nih.gov/)
were analysed for disease-speciﬁc survival according to their myoferlin gene expression split into low (N= 220) and high (N= 220) according to the
median. Kaplan–Meier curves were calculated for each group and a log-rank probability was calculated. b Myoferlin gene expression was analysed
according to the prognostic stage. c Twenty-eight COAD sections were stained and scored for myoferlin (0—no staining, 1—faint staining, 2—
medium staining, 3—strong staining). Scores were evaluated for tumour tissue and healthy adjacent
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Fig. 2 Myoferlin silencing in COAD cell lines reduces oxygen consumption rate (OCR) and disorganises mitochondrial network. a Kinetic
OCR response of HCT116 and SW480 to oligomycin (O, 1 μM), carbonyl cyanide-p-triﬂuoromethoxyphenylhydrazone (F, 1.0 μM), rotenone, and
antimycin A mix (RA, 0.5 μM each). Upon assay completion, cell number was evaluated using Hoechst incorporation (arbitrary unit, A.U.). b
Tetramethyl rhodamine ethyl ester (TMRE) was used to stain mitochondria in HCT116 and SW480 living cells. At 48 h post-transfection, cells were
seeded in μ-Slides 8-well at low conﬂuence, then loaded with TMRE (1 nM). c Immunodetection of dynamin-related protein (DRP)-1 or phospho-DRP-
1 in myoferlin-silenced HCT116 and SW480 cell lines. Total protein extracts (10 μg) were subjected to sodium dodecyl sulphate–polyacrylamide gel
electrophoresis followed by western blot analysis with speciﬁc antibodies against myoferlin, DRP-1, or phospho-DRP-1 (ser616). HSC-70 was used as a
loading control. One representative experiment out of three is illustrated. Each data point represents mean ± SD, n= 3. ****P < 0.0001, ***P < 0.001,
**P < 0.01, *P < 0.05
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activated by c-Jun N-terminal kinase during ROS-
induced DNA damage response22,23. In HCT116 cell
line (wild-type p53), myoferlin silencing induced a two-
fold increase of p53 abundance and a 2.4–4.7-fold
increase of its phosphorylation on Thr81, culminating in
a 2-fold increase of p21 abundance. Conversely, in
SW480 cell line (mutated p53), myoferlin silencing did
not alter the p53 abundance. In this cell line, p53 Thr81
phosphorylation was undetectable, as previously
described24. Based on the p53 activation and p21
abundance increase, suggesting a cell cycle arrest, we
decided to analyse the abundance of cyclins (Fig. 4b). In
HCT116 cell line, myoferlin silencing provoked an
accumulation in cyclin A (S-G2 cyclin) and B (mitotic
cyclin). In SW480 cell line, no consistent cyclin mod-
ulation was observed after myoferlin depletion. In order
to explore the cell cycle, HCT116 and SW480 cell lines
were stained with propidium iodide and analysed by
ﬂow cytometry (Fig. 4c). It appeared that myoferlin
silencing in HCT116 elicited an accumulation of cells in
S phase, suggesting a blockage of the S to G2 transition.
Myoferlin silencing induces a DNA damage response
The induced Thr81 phosphorylation of p53 in HCT116
upon myoferlin silencing prompted us to evaluate the cell
DNA damage response. HCT116 and SW480 cell lines were
Fig. 3 Effects of myoferlin silencing on cell physiology. a Reactive oxygen species accumulation in HCT116 and SW480 cells after myoferlin
silencing. At 48 h after myoferlin silencing, cells were harvested and loaded with CM-H2DCFDA (2 μM) for 15 min at 37 °C. Then ﬂuorescence was
measured by ﬂow cytometry and analysed as median ﬂuorescence intensity. b HCT116 and SW480 cell growth was assayed by Hoechst incorporation
and indirect DNA quantiﬁcation. Each data point represents mean ± SD, n= 3. c Percentage of apoptotic HCT116 or SW480 cells was measured by
annexin V/propidium iodide ﬂow cytometry. Insert represents the same data with a speciﬁc scale. ***P < 0.001, **P < 0.01, *P < 0.05
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immunostained for γH2Ax and observed under a confocal
microscope. In both cell lines, γH2Ax foci appeared in the
nucleus of myoferlin siRNA-transfected cells (Fig. 5a). Foci
quantiﬁcation indicated an increase of the foci number and
of the foci size after myoferlin silencing in both cell lines
(Fig. 5b). The accumulation of γH2Ax in transfected cells
was also observed by western blot with a ten-fold
accumulation in HCT116 and a two-fold accumulation in
SW480 (Fig. 5c).
Myoferlin silencing induces a p53-dependent reduction of
cell growth
In order to conﬁrm the participation of p53 in the
effects of myoferlin silencing, we took advantage of a
Fig. 4 Effects of myoferlin silencing on p53 activation and cell cycle progression. a p53 activation by Thr81 phosphorylation and subsequent
p21 abundance were evaluated in HCT116 and SW480 48 h after myoferlin silencing. b Cyclin abundance was evaluated by western blot in HCT116
and SW480 48 h after myoferlin silencing. Total protein extracts (10 μg) were subjected to sodium dodecyl sulphate–polyacrylamide gel
electrophoresis followed by western blot analysis with speciﬁc antibodies. HSC-70 was used as a loading control. c Cell cycle was analysed by ﬂow
cytometry after propidium iodide incorporation in HCT116 and SW480 48 h after myoferlin silencing. Distribution of FL2 ﬂuorescence (propidium
iodide) is shown in HCT116. Proportion of cells in G1, S, or G2 is shown in HCT116 and SW480. One representative experiment out of three is
illustrated. *P < 0.05
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Fig. 5 Myoferlin silencing induces a DNA damage response. a HCT116 and SW480 cell lines, silenced for myoferlin during 48 h, were stained for
γH2Ax and observed under a confocal microscope. b γH2Ax foci number and size were quantiﬁed using ImageJ. Number and size distributions were
established (n > 210 nuclei). c γH2Ax abundance was evaluated by western blot in HCT116 and SW480 48 h after myoferlin silencing. Total protein extracts
(10 μg) were subjected to sodium dodecyl sulphate–polyacrylamide gel electrophoresis followed by western blot analysis with speciﬁc antibodies. HSC-70
was used as a loading control
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HCT116 cell line deleted for p53 (HCT116 Δp53) and of
SW480 cell treated with a p53-reactivating molecule
(Prima-1). HCT116 Δp53 and Prima-1-treated SW480
were characterised for their myoferlin abundance and p53
and p21 status by western blot (Supplementary Figure S5).
HCT116 Δp53 seemed to have slightly more myoferlin
than the control HCT116 cell line. Myoferlin silencing in
HCT116 Δp53 did not alter the percentage of apoptotic
cells (Fig. 6a) but partly inhibited the HCT116 Δp53 cell
growth (Fig. 6b). In SW480 treated with Prima-1, myo-
ferlin silencing induced a slight but signiﬁcant increase of
the percentage of apoptotic cells (Fig. 6a). In these con-
ditions, cell growth was strongly affected (Fig. 6b). These
results clearly showed that p53 deletion from a p53 wild-
type cell line (HCT116) or p53 chemical reactivation in a
p53 mutant cell line (SW480) completely reversed the
apoptotic (Fig. 7a) and growth phenotypes (Fig. 7b)
observed after myoferlin silencing. Accordingly, it
appeared to us that removing myoferlin should be more
advantageous in p53 wild-type patients.
Myoferlin expression is associated with p53 mutation
status in colon cancer patients
Inspired by these results, we decided to go back to the
TCGA-COAD dataset used initially and mined for an
association between myoferlin expression and p53 mutation
status. In the present dataset, patient survival was not
associated with the p53 mutation status (Fig. 8a). However,
when myoferlin expression (low vs high) was combined to
the p53 mutation status (wild type vs mutated), a signiﬁcant
difference was found (Fig. 8b). The difference in survival
remained statistically signiﬁcant when myoferlin low–wild-
type patients were compared to the myoferlin high–p53-
mutated ones (Fig. 8c). Interestingly, myoferlin expression
was signiﬁcantly higher in p53 wild-type patients than in
p53-mutated ones (Supplementary Figure S6).
Discussion
Most cancer cells have a glucose-oriented metabolism,
preferring to use glycolysis to OXPHOS to grow. However, a
successful growth requests a metabolic ﬂexibility assured by
the preservation of several functional catabolic or ana-
plerotic pathways. The discovery that resistance to treat-
ment rely on OXPHOS in several cancer types5,25–28,
including colon cancer5, recently drew our attention to the
importance of identifying the elements rewiring metabolism
towards OXPHOS. Targeting OXPHOS in cancer cells
appears relevant8 as demonstrated by the use of VLX600 in
colon cancer cell lines9. This compound is an iron chelator29
and inhibits respiratory complexes I, II, and IV9.
Fig. 6 Myoferlin silencing induces reduction of cell growth after p53 restoration. a Percentage of apoptotic HCT116 Δp53 cells or SW480 cells
treated during 8 h with Prima-1 was measured by annexin V/propidium iodide ﬂow cytometry 48 h after myoferlin silencing. b Cell growth of
HCT116 Δp53 or SW480 treated during 8 h with Prima-1 was assayed by Hoechst incorporation and indirect DNA quantiﬁcation 48 h after myoferlin
silencing. Each data point represents mean ± SD, n= 3. ****P < 0.0001, **P < 0.01, *P < 0.05
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Interestingly, due to its antitumour activity in human
xenografts9,30, this compound was authorised in phase I in
patients with refractory advanced solid tumours (clinical
trials identiﬁer NCT02222363).
Myoferlin is an emerging tumour-promoting protein
described in several cancer types12,13,20,31–36, where it was
often associated with a poor prognosis14,16,17,20,33,34,36.
Interestingly, upon interleukin-6 stimulation myoferlin
binds to the oncogenic protein signal transducer and
activator of transcription factor 3 (STAT3) and partici-
pates in its nuclear translocation37. In colon cancer,
STAT3 activation is associated with an increased pro-
liferation rate, tumour growth, and a reduced survival38,39.
We have recently reported that myoferlin contributes to
growth factor exocytosis14, exosome fusion to recipient
cell15, lipid metabolism16, and mitochondrial ﬁtness17. In
the current study, we are investigating the involvement of
this protein in colon cancer where it was only described at
the exosome level40. Our results highlight for the ﬁrst
time an association between myoferlin expression and
survival of colon cancer patients and show a consistent
higher expression of this protein in tumour tissue in
comparison with the non-tumoural adjacent one.
Myoferlin silencing in colon cancer cells reduces
OXPHOS activity and disturbs the mitochondrial dynamics
leading to mitochondrial ﬁssion. This process is mainly
controlled by DRP-1 phosphorylation catalysed by several
kinases, including the mitogen-activated protein kinase
extracellular signal–regulated kinase 1/2 (ERK1/2)41.
Interestingly, myoferlin depletion in hepatocellular carci-
noma cells leads to ERK activation42 and a cleavable myo-
ferlin is required for ERK phosphorylation in HEK293
cells43. We have previously reported this perturbation of the
myoferlin-related mitochondrial dynamics in pancreas
cancer17. However, unlike in pancreas, myoferlin silencing
induced a low but consistent and signiﬁcant accumulation
of mitochondrial ROS. The cell-speciﬁc growth and the
apoptosis observed after myoferlin silencing prompt us to
consider their p53 mutation status.
Tumour-suppressor TP53 is the second most frequent
mutated gene in colon cancer. TP53 mutations were occa-
sionally described as being associated with low overall sur-
vival44,45. In our study, TCGA-COAD data did not associate
TP53 mutation status to the patient survival conﬁrming
previously reported observation46. Despite, the lack of con-
sistency in the relation between TP53 mutation and survival,
several small molecules were designed for reactivation of
p53. These promising compounds are currently tested in
clinical trials for hematologic malignancies and suppresses
colorectal cancer growth in xenograft mice47,48.
P53 protein is the core of a network of pathways in which
ROS play critical roles. Upstream of p53, production of ROS
Fig. 7 Myoferlin silencing induces a p53-dependent reduction of cell growth. a Comparison of apoptosis induction between HCT116 and
HCT116 Δp53 cells and between SW480 and Prima-1 treated SW480 48 h after myoferlin silencing. Irrelevant siRNA was used as control (100%). b
Comparison of 96 h cell growth between HCT116 and HCT116 Δp53 cells and between SW480 and Prima-1 treated SW480 after myoferlin silencing.
Irrelevant siRNA was used as control (100%). ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05
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is a fundamental mechanism of DNA damage and con-
stitutes a trigger for p53 activation49. It appears that the
wild-type p53 cells had their cell cycle stalled in S phase
upon myoferlin silencing, whereas mutated p53 cells were
not inﬂuenced. The reversion of the phenotype observed
upon myoferlin depletion by modulating p53 activity or
presence conﬁrms the role of p53.
To our knowledge, the current study demonstrates for
the ﬁrst time that myoferlin silencing results in DNA
damage probably due to ROS production by the frag-
mented mitochondria50. Interestingly, it has been pre-
viously shown that therapeutic agents generating ROS are
more likely to be toxic for wild-type p53 tumour cells51.
Accordingly, p53 reactivation increased the efﬁciency of
myoferlin silencing on cell growth inhibition.
The cell growth arrest and the apoptosis generated by
myoferlin silencing in p53 efﬁcient cell line could open up
new perspectives in the development of multi-modal
therapies associating p53 and myoferlin targeting. In light
of our results, about 75% of COAD patients exhibit a
myoferlin higher expression at the protein level and, in
consequence, can be considered as eligible to a myoferlin-
targeted therapy. Considering a p53 mutation incidence of
about 50%, half of the patients expressing myoferlin could
beneﬁt of the proposed multi-modal strategy. Currently,
p53 restoration drugs are under clinical trials and C2-
domain-targeting compounds are under development52.
While we were preparing this manuscript, a study
reported a small molecule targeting myoferlin with sig-
niﬁcant antitumour effect on breast cancer and on several
other cancer cell types, including pancreas cancer, pros-
tate cancer, and ovarian cancer53. This compound exerts
promising antimetastatic activity at nanomolar con-
centration most probably by its interaction with the C2D
Fig. 8 Disease-speciﬁc survival is associated with myoferlin expression and p53 mutation status in colon cancer patients. a TCGA-COAD
data were analysed for survival according to their p53 mutation status. b, c TCGA-COAD data were analysed for survival according to their p53
mutation status in combination with myoferlin expression. Kaplan–Meier curves were calculated for each group and a log-rank probability was
calculated
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domain of myoferlin. Together with our results, this dis-
covery adds weight to the potential of myoferlin to be
used as a relevant target for new anticancer therapies.
Materials and methods
Cells and chemicals
Human colon caner cells HCT116 (ATCC CCL-247)
and SW480 cells (ATCC CCL-228) were purchased from
ATCC. Cells were authenticated by Short-Tandem Repeat
proﬁling (DSMZ, Braunschweig, Germany). All reagents
were purchased from Sigma (Bornem, Belgium) unless
mentioned otherwise. Antibodies were purchased from
Sigma Life Sciences (Bornem, Belgium): myoferlin
(HPA014245); Santa Cruz Biotechnology (Santa Cruz,
CA): HSC70 (sc-7298), p21 (sc-6246), DRP-1 (sc-271583),
Cyclin B1 (sc-752); Cell Signaling (Danvers, MA):
phospho-DRP-1 (Ser616) (4494), phospho-p53 (Thr81)
(2676), γH2A.X (9718), Cyclin D1 (2978); Merck-
Millipore (Darmstadt, Germany): mitochondria
(MAB1273), p53 clone BP53–12 (05–224); BD Bios-
ciences: Cyclin A (611268), Cyclin E (551159).
Cell culture
HCT116 cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium supplemented with fetal bovine serum
(10% FBS). SW480 cells were cultured in Minimum
Essential Medium (MEM) supplemented with FBS (10%),
L-glutamine (2 mM), sodium pyruvate (1 mM), and non-
essential amino acids for MEM (Gibco #11140-085). Cells
were cultured in a 37 °C, 5% CO2 incubator. Cells were
recently authenticated and used between passage 1 and 10
and checked monthly for mycoplasma.
SiRNA transfection
HCT116 and SW480 cells were transfected with 40 nM
siRNA, respectively, using calcium phosphate or lipo-
fectamine as described previously17,54. All experiments
were performed 48 h after transfection.
Western blotting
Cells were lysed in sodium dodecyl sulphate (SDS; 1%)
in the presence of protease and phosphatase inhibitors.
SDS-polyacrylamide gel electrophoresis were performed
as described previously16. Band quantiﬁcations were per-
formed with the Image Studio Lite software v5.2.5 (LI-
COR Biosciences).
Extracellular ﬂux analysis
All experiments were performed with a Seahorse XFp
extracellular ﬂux analyser (Agilent). Cells were seeded
(20,000 cells/well) in XFp mini-plates (Agilent) and
allowed to attach overnight. Mitochondrial OCR (pmoles/
min) were measured as previously described17. Results
were normalised according the cell number evaluated by
Hoechst (2 µg/mL) incorporation. Results shown are
representative ones out of three independent experiments.
Mitochondrial TMRE staining
TMRE was used to stain mitochondria in living cells
as described previously17. Images were acquired by
epiﬂuorescence microscopy as Z-stacks with a Nikon
A1R microscope equipped with ×100 Oil objective.
Mitochondrial network was quantitatively assessed
using image analyses with the MiNA Fiji plugin55.
Results shown are representative ones out of three
experiments.
Immunoﬂuorescence
After siRNA transfection, 5 × 104 cells were seeded on
sterile glass coverslips. Forty-eight hours after transfec-
tion, cells were washed, ﬁxed, and then blocked as
described17. Coverslips were incubated overnight at 4 °C
with the primary antibody against γH2Ax diluted in
phosphate-buffered saline–bovine serum albumin solu-
tion. Coverslips were washed and incubated with Alexa-
ﬂuor 546 conjugated secondary antibody for 1 h at room
temperature. Sections were mounted following washes
and nuclei staining with Hoechst (10 ng/mL). Z-stack
images were acquired using a Nikon A1R confocal
microscope equipped with a Nikon ×100 Oil objective.
Results shown are representative ones out of three
experiments.
Mitochondrial ROS measurement
Mitochondrial ROS production was measured by ﬂow
cytometry using Mitosox (Invitrogen) ﬂuorescent probe
according to the manufacturer’s protocol. Results shown
are cumulative ones from three independent experiments.
Annexin V/propidium iodide staining
Percentage of apoptotic cells was assessed by ﬂow
cytometry using ﬂuorescein isothiocyanate-annexin V and
propidium iodide staining (BD Biosciences, Franklin
Lakes, NJ) according to the manufacturer’s instructions.
Results shown are cumulative ones from three indepen-
dent experiments.
Cell cycle analysis
Cell were trypsinised, washed once with PBS and then
ﬁxed with ice-cold 70% ethanol for 4h at 4 °C. Fixed cells
were washed once with PBS, then treated with RNAse
(50µg/mL) and stained with propidium iodide (50 µg/mL)
for 30 min at room temperature. Cells were analysed by
ﬂow cytometry with FACS calibur (BD Biosciences,
Franklin Lakes, NJ). Results shown are cumulative ones
from three independent experiments.
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Cell growth
Equal number of cells were seeded in complete medium
after transfection and harvested after 48 h. The cell
numbers were indirectly determined using Hoechst
incorporation. Results were expressed as DNA content.
Results shown are representative ones out of three
experiments.
Immunochemistry and staining assessment
Primary colon tumours were obtained from our institu-
tion Biobank, as formalin-ﬁxed, parafﬁn-embedded tissue
blocks. Sections were stained with antibodies against myo-
ferlin. Sections were then reviewed and scored blindly by
three independent investigators (G.R., M.H., and O.P.).
Myoferlin scoring was performed by evaluating the intensity
(ranging from 0 to 3) of each immunolabelled sample.
Chorioallantoic membrane assay (CAM)
HCT116 cells were grown on CAM for 7 days as pre-
viously mentioned14,56 and then tumour volumes have
been calculated as an ellipsoid. Ten CAM were grafted in
each experimental condition. Results shown are repre-
sentative ones out of three experiments.
Statistics
Kaplan–Meier survival curves were established based on
TCGA-COAD data. Survival curves were compared using
the log-rank test. All other results are reported as means
with standard deviation (SD). Two-sided statistical ana-
lyses were performed using one-way or two-way analysis
of variance depending on the number of grouping factors.
Unless mentioned otherwise, group means were com-
pared by unpaired Student’s t test or Bonferroni’s post-
test according to the group number. Welsch’s correction
was applied when homoscedasticity was suspected. P <
0.05 was considered as statistically signiﬁcant. Unlabelled
differences between groups were non-signiﬁcant. All
experiments were performed as several independent bio-
logical replicates. Statistics were performed using R v3.457.
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